Camber Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Camber Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-525,000	Closed	-$11.6M	–	43
2020 Q4	$11.6M	Hold	525,000	–	–	0.41%	30
2020 Q3	$9.45M	Buy	+525,000	New	+$10.9M	0.5%	30
2018 Q2	–	Sell	-1,000,000	Closed	-$9.56M	–	38
2018 Q1	$9.56M	Hold	1,000,000	–	–	0.47%	29
2017 Q4	$9.03M	Buy	+1,000,000	New	+$7.36M	0.44%	30

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Camber Capital Management's DRNA Position: Q1 2021 in Review

Camber Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2021, closing a stake of 525,000 shares — an estimated $11.6M sold.

Camber Capital Management first reported a position in DRNA in Q4 2017 and held it in 4 quarters. The position peaked at $11.6M in Q4 2020. 183 funds tracked by Wall St. Rank hold DRNA as of Q1 2021.

Camber Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
Camber Capital Management sold 525,000 Dicerna Pharmaceuticals, Inc. shares in Q1 2021, an estimated $11.6M.
Camber Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
Camber Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $11.6M in Q4 2020.
183 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2021.

Based on Camber Capital Management's 13F filing for Q1 2021, filed 17 May 2021.